Fabtech Technologies Ltd

Q4 FY27 Earnings Call Analysis

Healthcare Services

Full Stock Analysis
fundraise: No informationcapex: Yesrevenue: Category 2margin: Category 3orderbook: Yes
🏗️

capex

Any current/future capex/capital investment/strategic investment?

- Fabtech Technologies Limited has raised funds through an IPO to invest in strategic areas. - The company is planning acquisitions in Europe, UAE, and Saudi Arabia to strengthen local presence and conversion rates. - Investments are being made to own processes, IPs, and increase ticket sizes for bigger turnkey projects. - Fabtech is focusing on infrastructure projects including green energy options like solar (tied up with KP Greens). - They are preparing to expand beyond life sciences into sectors like data centers and semiconductors when the time is right. - The company is investing in building a strong design platform across process, air, and water domains with homegrown companies. - Capital is being allocated towards marketing and business development (8.5 to 9 crores annually) with some flexibility. - Preparing for expedited civil construction by clients to improve conversion and execution. - Exiting TSA Process Equipments Pvt Ltd (water solutions) in the current financial year as part of capital allocation strategy.
📊

revenue

Future growth expectations in sales/revenue/volumes?

- Fabtech Technologies targets a year-on-year growth of **30%** starting FY27 (Page 16). - Execution of a **900 crore order book** is expected mostly in the next financial year, with about **30-40% spilling into Q1/Q2 FY28** (Page 16). - Average ticket size has increased to between **7 to 10 million dollars**, up from earlier 1.5 to 3 million dollars, boosting volumes and margins (Page 9, 22). - Increased presence and leveraging of markets in **UAE, Saudi Arabia, and eco-African regions** to drive volume growth and margin improvement (Page 22). - The company aims to capitalize on the growing medicinal independence movement in emerging markets, expanding its life sciences infrastructure footprint (Page 14). - Growth is supported by in-house design and manufacturing capabilities, and potential acquisitions further strengthening market position (Page 13). - Quarterly fluctuations expected, but annual growth guidance remains intact (Page 13).
📈

margin

Future growth expectations in earnings/operating earnings/profits/EPS?

- Profit After Tax (PAT) margins are expected to remain between 9% to 11%. - There is flexibility to improve margins by rationalizing marketing and business development expenses, currently around ₹8.5 - 9 crores annually. - Operating profit margins are anticipated to benefit from increased ticket sizes, with orders moving from $1.5–3 million to $7–10 million. - Higher ticket sizes and expanded geographic leverage (UAE, Saudi, Eco-African region) are expected to enhance volumes and operating margins. - The company's focus on life sciences infrastructure and growing market presence in emerging geographies indicates sustained revenue growth. - Strong order book (₹900 crore) with execution expected to pick up by Q1 FY28 supports growth visibility. - Operating cash flow may remain negative during high growth phases due to working capital cycles but is expected to improve post-growth stabilization. - EPS growth likely aligns with PAT growth guided between ₹39–41 crores for FY26.
📋

orderbook

Current/ Expected Orderbook/ Pending Orders?

- As of January end, the order book stands at approximately INR 926 crore. - The order book is almost entirely export-focused, targeting international markets, primarily in emerging economies. - The company has a healthy pipeline of hot leads valued around USD 455 million. - Execution timeline for the current order book is expected to span 9 to 18 months, with efforts underway to expedite deliveries. - Major portion of the order book is expected to be executed in the next financial year, with roughly 30-40% spilling over into Q1 or Q2 of FY28. - The average ticket size of orders is increasing, currently around USD 7 million, with hot leads ranging between USD 7 to 10 million. - Order inflow has remained strong without cancellations or pricing pressures, signaling sustained demand.
💰

fundraise

Any current/future new fundraising through debt or equity?

- Fabtech Technologies Limited has raised funds through an IPO recently, with funds parked in Fixed Deposits earning interest (other income). - There is no explicit mention of imminent new fundraising through equity or debt in the transcript. - The company is focusing on executing existing orders and growing organically, including through acquisitions. - They have a "war chest for acquisitions," implying availability of funds for strategic purchases. - No specific new equity or debt raising plans were stated for the near future during the call.